IL17A and myeloid sarcoma: Hania Kebir et al. demonstrated the expressions of IL-17 and IL-22 receptors on the BBB endothelial cells within MS lesions, thus indicating their involvement in disrupting the tight junctions (TJs) of BBB (33).